Pomalidomide in the management of relapsed multiple myeloma

Abstract : Pomalidomide, a very potent member of the immunomodulatory drug family, is considered a standard of care for patients with relapsed and refractory myeloma, who have previously been treated with bortezomib and lenalidomide. Pomalidomide induces both direct myeloma cell death, and indirect antimyeloma response through its impact on the microenvironment (modulation of immune response, inhibition of angiogenesis, inhibition of bone resorption). Pomalidomide in combination with dexamethasone is an approved regimen in Europe and USA based on the results of a Phase III randomized trial. In order to improve response rate and patient survival, pomalidomide is currently being assessed in triplet combinations with other antimyeloma agents. The present review addresses current knowledge regarding the clinical use of pomalidomide in relapsed myeloma patients.
Type de document :
Article dans une revue
Future Oncology, Future Medicine, 2016, 〈10.2217/fon-2016-0184〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01411106
Contributeur : Elizabeth Bernardo <>
Soumis le : mercredi 7 décembre 2016 - 09:17:57
Dernière modification le : jeudi 15 mars 2018 - 14:12:14

Identifiants

Collections

Citation

Cyrille Touzeau, P. Moreaux. Pomalidomide in the management of relapsed multiple myeloma. Future Oncology, Future Medicine, 2016, 〈10.2217/fon-2016-0184〉. 〈inserm-01411106〉

Partager

Métriques

Consultations de la notice

33